CA2584207A1 - Oligonucleotides antiviraux - Google Patents

Oligonucleotides antiviraux Download PDF

Info

Publication number
CA2584207A1
CA2584207A1 CA002584207A CA2584207A CA2584207A1 CA 2584207 A1 CA2584207 A1 CA 2584207A1 CA 002584207 A CA002584207 A CA 002584207A CA 2584207 A CA2584207 A CA 2584207A CA 2584207 A1 CA2584207 A1 CA 2584207A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
virus
antiviral
rep
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002584207A
Other languages
English (en)
Inventor
Jean-Marc Juteau
Andrew Vaillant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replicor Inc
Original Assignee
Replicor, Inc.
Jean-Marc Juteau
Andrew Vaillant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/969,812 external-priority patent/US20050196382A1/en
Application filed by Replicor, Inc., Jean-Marc Juteau, Andrew Vaillant filed Critical Replicor, Inc.
Publication of CA2584207A1 publication Critical patent/CA2584207A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002584207A 2004-10-19 2005-10-19 Oligonucleotides antiviraux Abandoned CA2584207A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/969,812 US20050196382A1 (en) 2002-09-13 2004-10-19 Antiviral oligonucleotides targeting viral families
US10/969,812 2004-10-19
US66898305P 2005-04-07 2005-04-07
US60/668,983 2005-04-07
PCT/CA2005/001623 WO2006042418A1 (fr) 2004-10-19 2005-10-19 Oligonucleotides antiviraux

Publications (1)

Publication Number Publication Date
CA2584207A1 true CA2584207A1 (fr) 2006-04-27

Family

ID=36202655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002584207A Abandoned CA2584207A1 (fr) 2004-10-19 2005-10-19 Oligonucleotides antiviraux

Country Status (5)

Country Link
EP (1) EP1802643A1 (fr)
JP (1) JP2008516996A (fr)
AU (1) AU2005297376A1 (fr)
CA (1) CA2584207A1 (fr)
WO (1) WO2006042418A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308514B1 (fr) 2007-03-23 2013-06-05 to-BBB Holding B.V. Conjugés pour le transport de médicaments à travers la barrière hémato-encéphalique
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
SG11201407599SA (en) * 2012-05-18 2014-12-30 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
TWI664187B (zh) * 2013-05-22 2019-07-01 阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
WO2016030863A1 (fr) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Composés et méthodes de traitement des infections virales
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
AU2021383758A1 (en) * 2020-11-20 2023-06-15 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022229350A2 (fr) 2021-04-30 2022-11-03 Tirmed Pharma Ab Oligonucléotides monocaténaires pouvant être utilisés dans le traitement médical et/ou la prophylaxie d'infections virales
EP4108771A1 (fr) * 2021-06-24 2022-12-28 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Oligonucléotides contenant un quadruplex g pour le traitement préventif et thérapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2547592A (en) * 1991-08-23 1993-03-16 Isis Pharmaceuticals, Inc. Synthetic unrandomization of oligomer fragments
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
MXPA05002791A (es) * 2002-09-13 2005-12-05 Replicor Inc Oligonucleotidos antivirales complementarios sin secuencia.

Also Published As

Publication number Publication date
EP1802643A1 (fr) 2007-07-04
AU2005297376A1 (en) 2006-04-27
WO2006042418A9 (fr) 2007-05-31
JP2008516996A (ja) 2008-05-22
WO2006042418A1 (fr) 2006-04-27

Similar Documents

Publication Publication Date Title
CA2498777C (fr) Oligonucleotides antiviraux non complementaires de sequence
CA2584207A1 (fr) Oligonucleotides antiviraux
CA2833778C (fr) Compositions et methodes permettant d'inhiber l'expression d'un gene du virus de l'hepatite b
US20100172965A1 (en) Antiviral oligonucleotides targeting viral families
JP2011130772A (ja) Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法
CN101084232A (zh) 抗病毒寡核苷酸
WO2006119643A1 (fr) Molecules contre l'angiogenese oculaire et leurs utilisations
CN1694959A (zh) 非序列互补的抗病毒寡核苷酸
MX2008005572A (es) Inhibicion de arni o replicacion del virus de influenza

Legal Events

Date Code Title Description
FZDE Dead